PCSK9 inhibitors: Current evidence, mechanisms and unanswered questions

Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of cardiovascular mortality worldwide after myocardial infarction and stroke. Despite continuous progress in anticoagulation, a specific preventive strategy against VTE that goes beyond anticoagulation is still lacking. In recent years, it has been shown that arterial and venous thromboembolism share more common risk factors than previously thought, including dyslipidemia and inflammatory processes.